<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313612</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00053</org_study_id>
    <secondary_id>NYU 03-67</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <nct_id>NCT00313612</nct_id>
  </id_info>
  <brief_title>Oxaliplatin and Topotecan in Advance Ovarian Cancer</brief_title>
  <official_title>A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving oxaliplatin together with topotecan works in&#xD;
      treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian&#xD;
      tube cancer. Drugs used in chemotherapy, such as oxaliplatin and topotecan, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate the overall clinical response rate (complete and partial responses) in patients&#xD;
      with previously treated ovarian epithelial, primary peritoneal, or fallopian tube cancer&#xD;
      treated with oxaliplatin and topotecan.&#xD;
&#xD;
      II. Determine the toxic effects in patients treated with this regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate the time to progression and overall clinical response duration in patients&#xD;
      treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study. Patients are stratified according to&#xD;
      response to prior platinum therapy (resistant vs sensitive).&#xD;
&#xD;
      Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously&#xD;
      on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response Rate (Complete and Partial Response by RECIST and/or CA [Cancer Antigen] 125)</measure>
    <time_frame>Every two cycles for up to 24 weeks.</time_frame>
    <description>Tumor response was assessed every two cycles by CT/MRI using RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;= 30% decrease in the sum of the longest diameter (LD) of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression by RECIST and/or CA 125</measure>
    <time_frame>Tumor measurements will be performed every 8 weeks until the date of first documented progression up to 100 weeks</time_frame>
    <description>Time to disease progression by RECIST and/or CA 125</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (oxaliplatin plus topotecan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oxaliplatin plus topotecan)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oxaliplatin plus topotecan)</arm_group_label>
    <other_name>hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>TOPO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed ovarian epithelial, primary peritoneal, or&#xD;
             fallopian tube cancer&#xD;
&#xD;
          -  Meets 1 of the following criteria for response to prior platinum-based therapy:&#xD;
&#xD;
               -  Platinum-resistant disease, defined as a disease-free interval of &lt; 6 months&#xD;
                  after prior platinum-based therapy OR progressive disease on a&#xD;
                  platinum-containing regimen&#xD;
&#xD;
               -  Platinum-sensitive disease, defined as a disease-free interval of &gt; 6 months&#xD;
                  after prior platinum-based therapy&#xD;
&#xD;
          -  Measurable or evaluable disease: Measurable disease is characterized as lesions&#xD;
             reproducibly measurable in 1 dimension; evaluable disease is defined as known disease&#xD;
             with CA125 levels &gt; 50 U/mL on 2 occasions &gt;= 1 week apart&#xD;
&#xD;
          -  Previously treated with a taxane and platinum-based regimen, only 1 prior&#xD;
             platinum-based regimen, including IV or intraperitoneal consolidation, one additional&#xD;
             non-platinum and non-topotecan chemotherapy regimen allowed&#xD;
&#xD;
          -  Life expectancy &gt;= 4 months&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST =&lt; 2.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 times ULN AND creatinine clearance &gt; 40 mg/dL&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  No presence of any other active cancer&#xD;
&#xD;
          -  No uncontrolled intercurrent illness, including the following:&#xD;
&#xD;
               -  Infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
          -  No history of severe allergy to platinum compounds&#xD;
&#xD;
               -  (Mild reaction (skin only) allowed provided a negative skin test is obtained)&#xD;
&#xD;
          -  No history of allergic reaction to appropriate antiemetics (e.g., 5HT3 antagonists)&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No prior radiotherapy to the whole pelvic field&#xD;
&#xD;
          -  No unresolved sequelae resulting from any surgical procedures&#xD;
&#xD;
          -  No concurrent colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim&#xD;
             [GM-CSF]) during topotecan infusion&#xD;
&#xD;
          -  No concurrent participation in another investigational trial&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Tiersten</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int J Gynecol Cancer. 2013 Nov;23(9):1577-82. doi: 10.1097/IGC.0b013e3182a809e0.</citation>
    <PMID>24172094</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>April 11, 2006</study_first_submitted>
  <study_first_submitted_qc>April 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <results_first_submitted>April 13, 2015</results_first_submitted>
  <results_first_submitted_qc>October 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2015</results_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 39 patients were enrolled from 3 institutions between January 2006 and October 2009</recruitment_details>
      <pre_assignment_details>1 patient never received treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Stratum I (Oxaliplatin Plus Topotecan)</title>
          <description>Treatment stratum I (oxaliplatin plus topotecan) is resistant to prior platinum therapy. Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Treatment Stratum II (Oxaliplatin Plus Topotecan)</title>
          <description>Treatment stratum II (oxaliplatin plus topotecan) is sensitive to prior platinum therapy. Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient never received treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Stratum I: (Oxaliplatin Plus Topotecan)</title>
          <description>Treatment stratum I (oxaliplatin plus topotecan) is resistant to prior platinum therapy. Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Treatment Stratum II (Oxaliplatin Plus Topotecan)</title>
          <description>Treatment stratum II (oxaliplatin plus topotecan) is sensitive to prior platinum therapy. Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="38" upper_limit="80"/>
                    <measurement group_id="B2" value="59" lower_limit="40" upper_limit="71"/>
                    <measurement group_id="B3" value="60" lower_limit="38" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response Rate (Complete and Partial Response by RECIST and/or CA [Cancer Antigen] 125)</title>
        <description>Tumor response was assessed every two cycles by CT/MRI using RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;= 30% decrease in the sum of the longest diameter (LD) of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Every two cycles for up to 24 weeks.</time_frame>
        <population>30 patients were analyzed. Eight patients discontinued treatment before 2 cycles.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Stratum I (Oxaliplatin Plus Topotecan)</title>
            <description>Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment Stratum II (Oxaliplatin Plus Topotecan)</title>
            <description>Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate (Complete and Partial Response by RECIST and/or CA [Cancer Antigen] 125)</title>
          <description>Tumor response was assessed every two cycles by CT/MRI using RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;= 30% decrease in the sum of the longest diameter (LD) of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>30 patients were analyzed. Eight patients discontinued treatment before 2 cycles.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression by RECIST and/or CA 125</title>
        <description>Time to disease progression by RECIST and/or CA 125</description>
        <time_frame>Tumor measurements will be performed every 8 weeks until the date of first documented progression up to 100 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Stratum I (Oxaliplatin Plus Topotecan)</title>
            <description>Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment Stratum II (Oxaliplatin Plus Topotecan)</title>
            <description>Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression by RECIST and/or CA 125</title>
          <description>Time to disease progression by RECIST and/or CA 125</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="2.6" upper_limit="7.1"/>
                    <measurement group_id="O2" value="12.6" lower_limit="4.3" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Stratum I (Oxaliplatin Plus Topotecan)</title>
          <description>Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Treatment Stratum II (Oxaliplatin Plus Topotecan)</title>
          <description>Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.&#xD;
oxaliplatin: Given IV&#xD;
topotecan: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>RBC transfusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelet transfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Escobar-Peralta</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-379-6866</phone>
      <email>lescobar@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

